Effect of CCR2-V64I on the Susceptibility of Patients to Cancer
Table 2
Results of overall and subgroups analyses for rs1799864 polymorphisms.
No
A versus G
AA versus GG
GA versus GG
AA+GA versus GG
AA versus GA+GG
OR
(95% CI)
P(Z)
OR
(95% CI)
P(z)
OR
(95% CI)
P(z)
OR
(95% CI)
P(z)
OR
(95% CI)
P(z)
Overall
26
1.39
1.14–1.70
0.001
1.87
1.30–2.70
0.001
1.35
1.03–1.78
0.032
1.45
1.11–1.90
0.006
1.69
1.20–2.37
0.003
European
4
0.89
0.57–1.38
0.603
0.98
0.26–3.71
0.982
0.86
0.58–1.26
0.436
0.87
0.56–1.34
0.522
0.99
0.28–3.48
0.990
Asian
14
1.57
1.30–1.91
<0.001
2.30
1.64–3.24
<0.001
1.35
1.10–1.67
0.005
1.52
1.25–1.87
<0.001
2.21
1.58–3.08
<0.001
BCa
2
0.75
0.41–1.36
0.336
0.62
0.23–1.64
0.332
0.73
0.38–1.41
0.343
0.72
0.37–1.41
0.341
0.67
0.25–1.78
0.421
BCb
5
1.42
0.93–2.18
0.107
3.04
1.09–8.45
0.033
1.29
0.91–1.83
0.160
1.41
0.93–2.13
0.109
2.84
1.07–7.49
0.035
CC
4
1.88
0.86–4.10
0.112
1.66
0.40–6.82
0.481
2.10
0.57–7.76
0.268
2.56
0.71–9.20
0.150
1.15
0.35–3.82
0.817
OCa
2
1.83
1.39–2.42
<0.001
1.93
0.85–4.40
0.118
2.04
1.47–2.85
<0.001
2.03
1.48–2.79
<0.001
1.63
0.72–3.70
0.242
PC
3
1.12
0.61–2.06
0.717
1.23
0.25–6.08
0.801
1.08
0.70–1.69
0.722
1.11
0.62–1.98
0.718
1.20
0.27–5.29
0.812
PB
8
1.20
0.86–1.68
0.291
1.87
0.75–4.67
0.177
1.13
0.85–1.50
0.396
1.19
0.85–1.66
0.304
1.80
0.78–4.16
0.171
HB
16
1.55
1.20–2.01
0.001
1.95
1.27–2.99
0.002
1.52
1.02–2.25
0.038
1.68
1.16–2.43
0.006
1.70
1.14–2.54
0.009
BCa: breast cancer; BCb: bladder cancer; CC: cervical cancer; OCa: oral cancer; PC: prostate cancer; PB: population-based study; HB: hospital-based study. The bold values given indicate that a significant relationship was discovered in the overall analyses and subgroup analyses.
